Paul D Miller MD
Distinguished Clinical Professor of Medicine, University of Colorado Health Sciences Center
Join to View Full Profile
6655 West Jewell AvenueSuite 2Lakewood, CO 80232
Phone+1 303-284-2352
Fax+1 303-284-2384
Dr. Miller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Nephrology, 1974 - 1976
University of Rochester Medical CenterChief Residency, Internal Medicine, 1973 - 1974- University of Rochester Medical CenterResidency, Internal Medicine, 1970 - 1973
George Washington University School of Medicine and Health SciencesClass of 1970
Certifications & Licensure
CO State Medical License 1974 - 2025
TX State Medical License 2023 - 2025
Clinical Trials
- Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates Start of enrollment: 2015 Jun 01
Roles: Contact
Publications & Presentations
PubMed
- 24 citationsAbaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.Ruban Dhaliwal, Didier Hans, Gary Hattersley, Bruce Mitlak, Lorraine A Fitzpatrick
JBMR Plus. 2020-04-01 - 4 citationsEstimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM an...Ethel S. Siris, Michele McDermott, Nicola Pannacciulli, Paul D. Miller, E. Michael Lewiecki
JBMR Plus. 2020-02-24 - 29 citationsAbaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.John P. Bilezikian, Gary Hattersley, Bruce H. Mitlak, Ming-yi Hu, Lorraine A. Fitzpatrick
Current Medical Research and Opinion. 2019-09-11
Press Mentions
Romosozumab Safe in Osteoporosis with Mild-Moderate Renal DiseaseOctober 19th, 2019
Romosozumab Benefits Osteoporosis Patients Regardless of Renal InsufficiencyOctober 7th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
